alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)January 26,
2009




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
                
                000-23143
                
                13-3379479(State
      or other jurisdiction
                  of
      incorporation)
                
                (Commission
                  File
      Number)
                
                (IRS
      Employer
                  Identification
      No.)777 Old Saw Mill River Road, Tarrytown, New
      York
                
                10591(Address
      of principal executive offices)
                
                (Zip
      Code)Registrant's telephone number,
      including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))




oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))











Item
8.01. Other Events.





Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics
collaborates in the development and commercialization of RELISTOR®, has
informed Progenics that global net sales of RELISTOR for the fourth quarter of
2008 were $1.5 million, as compared to $0.8 million in the third quarter of
2008. Wyeth began full promotion of RELISTOR in mid-August, under a
program that included sales detailing, the offering of early experience trial
kits and company-directed educational programs.  Global net sales for 2008,
which commenced in June, totaled $4.4 million.





RELISTOR
is the first drug in a novel class for a completely new therapeutic use –
opioid-induced constipation.  The approved indication for RELISTOR
addresses the needs of individuals with advanced illness receiving palliative
care.  Ongoing clinical studies have the goal of expanding the use of
RELISTOR in other patient settings.











SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.






PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A.
McKinney


Chief Financial Officer, Senior
Vice President,


Finance & Operations and
Treasurer






Date:  January
26, 2009
#### In the Matter of John J. Beechwood, an Attorney, Respondent. Association of the Bar of the City of New York, Petitioner.

First Department,

June 11, 1943.

*Binar Chrystie*for petitioner.

No appearance for respondent.

*278
      *Per Curiam.*

On February 25, 1941, in the Court of General Sessions of the County of New York, the respondent pleaded guilty of the crime of grand larceny in the first degree. On January 23,1942, in the Court of General Sessions of the County of New York, the respondent pleaded guilty of another crime of grand larceny in the first degree. Said crimes are felonies. Pursuant to subdivision 3 of section 88 and section 477 of the Judiciary Law, therefore, he should be disbarred.

Martin, P. J., Townley, Untermyer, Cohn and Callahan, JJ., concur.

Respondent disbarred.
### §8513. Tornado warning improvement and extension program

#### (a) In general

The Under Secretary, in collaboration with the United States weather industry and academic partners, shall establish a tornado warning improvement and extension program.

#### (b) Goal

The goal of such program shall be to reduce the loss of life and economic losses from tornadoes through the development and extension of accurate, effective, and timely tornado forecasts, predictions, and warnings, including the prediction of tornadoes beyond 1 hour in advance.

#### (c) Innovative observations

The Under Secretary shall ensure that the program periodically examines the value of incorporating innovative observations, such as acoustic or infrasonic measurements, observations from phased array radars, and observations from mesonets, with respect to the improvement of tornado forecasts, predictions, and warnings.

#### (d) Program plan

Not later than 180 days after April 18, 2017, the Assistant Administrator for Oceanic and Atmospheric Research, in coordination with the Director of the National Weather Service, shall develop a program plan that details the specific research, development, and technology transfer activities, as well as corresponding resources and timelines, necessary to achieve the program goal.

#### (e) Annual budget for plan submittal

Following completion of the plan, the Under Secretary, acting through the Assistant Administrator for Oceanic and Atmospheric Research and in coordination with the Director of the National Weather Service, shall, not less frequently than once each year, submit to Congress a proposed budget corresponding with the activities identified in the plan.

(Pub. L. 115–25, title I, §103, Apr. 18, 2017, 131 Stat. 94; Pub. L. 117–316, §8, Dec. 27, 2022, 136 Stat. 4412.)

#### **Editorial Notes**

#### Amendments

2022—Subsecs. (c) to (e). Pub. L. 117–316 added subsec. (c) and redesignated former subsecs. (c) and (d) as (d) and (e), respectively.